Synthesis 2014; 46(10): 1399-1406
DOI: 10.1055/s-0033-1340980
paper
© Georg Thieme Verlag Stuttgart · New York

Scalable and Cost-Effective Synthesis of a Linker for Bioconjugation with a Peptide and a Monoclonal Antibody

Authors

  • Javier Magano*

    a   Chemical Research & Development, Pfizer Worldwide Research & Development, Eastern Point Road, Groton, CT 06340, USA   Fax: +1(860)7158593   Email: Javier.Magano@Pfizer.com
  • Brian G. Conway

    a   Chemical Research & Development, Pfizer Worldwide Research & Development, Eastern Point Road, Groton, CT 06340, USA   Fax: +1(860)7158593   Email: Javier.Magano@Pfizer.com
  • Douglas Farrand

    b   Analytical Research & Development, Pfizer Worldwide Research & Development, Eastern Point Road, Groton, CT 06340, USA
  • Michael Lovdahl

    b   Analytical Research & Development, Pfizer Worldwide Research & Development, Eastern Point Road, Groton, CT 06340, USA
  • Mark T. Maloney

    a   Chemical Research & Development, Pfizer Worldwide Research & Development, Eastern Point Road, Groton, CT 06340, USA   Fax: +1(860)7158593   Email: Javier.Magano@Pfizer.com
  • Mark J. Pozzo

    c   Biotherapeutics Pharmaceutical Sciences, Pfizer Worldwide Research & Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA
  • John J. Teixeira

    a   Chemical Research & Development, Pfizer Worldwide Research & Development, Eastern Point Road, Groton, CT 06340, USA   Fax: +1(860)7158593   Email: Javier.Magano@Pfizer.com
  • John Rizzo

    d   CovX Research, 9381 Judicial Drive, San Diego, CA 92121, USA
  • David Tumelty

    d   CovX Research, 9381 Judicial Drive, San Diego, CA 92121, USA
Further Information

Publication History

Received: 24 January 2014

Accepted after revision: 20 February 2014

Publication Date:
17 March 2014 (online)


Graphical Abstract

Preview

Abstract

An efficient, scalable, and cost-effective synthesis of a linker employed in a bioconjugation process with a peptide and a monoclonal antibody is presented. Several routes were investigated that resulted in the identification of a short synthesis to a key acid intermediate from inexpensive and readily available starting materials. The final coupling of this acid with an aniline to afford the desired linker has been optimized to produce multi-gram quantities of material for clinical studies. The very limited purifications needed for both intermediates and final product make this route amenable to scale.

Supporting Information